Copy Link Print Information

Cyclophosphamide hydrate

(Synonyms: Cyclophosphamide monohydrate)
78 Cited Publications
Customer Review

Based on 78 publication(s) in Google Scholar

Cyclophosphamide hydrate is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.

For research use only. We do not sell to patients.

  • Purity: 99.97%
  • CAS No.: 6055-19-2
  • Formula: C7H17Cl2N2O3P
  • Molecular Weight:279.10
  • Storage:

    4°C, sealed storage, away from moisture

    * The compound is unstable in solutions, freshly prepared is recommended.

  • Cyclophosphamide hydrate Chemical Structure
    Cyclophosphamide hydrate Chemical Structure
  • Experimental Validation Results for Cyclophosphamide hydrate
  • Experimental Validation Results for Cyclophosphamide hydrate
  • Experimental Validation Results for Cyclophosphamide hydrate
  • Experimental Validation Results for Cyclophosphamide hydrate
  • Experimental Validation Results for Cyclophosphamide hydrate
  • Experimental Validation Results for Cyclophosphamide hydrate
  • Experimental Validation Results for Cyclophosphamide hydrate
  • Experimental Validation Results for Cyclophosphamide hydrate
  • Experimental Validation Results for Cyclophosphamide hydrate
  • Experimental Validation Results for Cyclophosphamide hydrate
CAS No.: 6055-19-2
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Cyclophosphamide hydrate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Cyclophosphamide hydrate

More
Customer Validation & Images
Apoptosis AnalysisCell Imaging/StainingWBCell Proliferation/Viability Assay
  • WB
  • Cell Proliferation/Viability Assay
  • Apoptosis Analysis
  • Cell Imaging/Staining
  • Cell Imaging/Staining
  • Cell Imaging/Staining
  • Cell Imaging/Staining
  • Cell Proliferation/Viability Assay
  • WB
  • WB
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Cyclophosphamide hydrate Chemical Structure
    Cyclophosphamide hydrate Chemical Structure
    1/16
  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: Apoptosis. 2025 Jun;30(5-6):1331-1350. [Abstract]

    Customer Validation
     Clophosphamide (Cy) (i.p.; the regimens consisting of an initial dose of 50 mg/kg, followed by a daily dose of 10 mg/kg for 14 days) upregulates mitochondrial apoptosis-related proteins (including Cleaved Caspase 9, Cleaved Caspase 3, and BAX) in the ovaries of C57BL/6J mice.

  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: Cell Biol Int. 2025 May 22. [Abstract]

    Customer Validation
     Using cell viability (MTT) experiments, the DBTRG‐05MG killer dose of Cyclophosphamide (CP; 0–4 mM; 24 h) was determined. We found that the 2 mM had a cell mortality rate of almost 80%.

  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: Cell Biol Int. 2025 May 22. [Abstract]

    Customer Validation
     Treatments with CAR prevented CP‐induced raising caspases and apoptosis through the inhibition of TRPM2 in DBTRG‐05MG. The CN, CAR (200 μM for 24 h), Cyclophosphamide (CP; 2 mM for 24 h), and their combination (CP + CAR) groups were investigated for apoptosis (A), caspase‐3 (B), caspase‐8 (C), and caspase‐9 (D).

  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: Cell Biol Int. 2025 May 22. [Abstract]

    Customer Validation
     The Cyclophosphamide (CP; 2 mM for 24 h) increased the proportion of PI‐positive DBTRG‐05MG, whereas the TRPM2 inhibitor (CAR, 200 μM for 24 h) decreased it. A fluorescent Axiocam 702 camera and a ×20 objective inverted microscope (Axio Observer.Z1/7) were used to capture the red (PI), blue (Hoechst), black/white (bright field, BF), overlay, and 2.5D images (A). A 10 μm scale bar was used. PI‐positive (death) cell counts were shown as percentages in columns (B).

  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: Cell Biol Int. 2025 May 22. [Abstract]

    Customer Validation
     CAR (200 μM for 24 h) reduced Cyclophosphamide (CP; 2 mM for 24 h)‐induced increases in mitochondrial membrane dysfunction (MiDYS) in DBTRG‐05MG. A fluorescent Axiocam 702 camera with a ×20 objective and inverted microscope (Axio Observer.Z1/7) was used to capture the red (MitoTracker), orange (JC‐1), black/white (bright field, BF), overlay, and 2.5D images (A). The bar on the scale was 10 m. The percentages of MiDYS (JC‐1) were shown in columns (B).

  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: Cell Biol Int. 2025 May 22. [Abstract]

    Customer Validation
     Cyclophosphamide (CP; 2 mM; 24 h)‐induced increases in mROS and iROS were decreased in DBTRG‐05MG by TRPM2 inhibition (CAR, 200 μM for 24 h). The red mROS (MitoSOX), green iROS (DCF), overlay, and 2.5D images were taken using the LSCM equipped with a×20 objective.

  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: Cell Biol Int. 2025 May 22. [Abstract]

    Customer Validation
     CAR (200 μM for 24 h) incubation reduced the increase in [Ca2+]i in the DBTRG‐05MG caused by Cyclophosphamide (CP; 2 mM for 24 h). After the cells were stained with Fluo‐3 AM (1 μM), they were stimulated with H2O2 (1 mM) for 60–90 s and subsequently inhibited in the LSCM with 200 μM CAR for 60–90 s.

  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]

    Customer Validation
     The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.

  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2021 Jan:183:114340. [Abstract]

    Customer Validation
     Clophosphamide (CYP) (75 mg/kg; i.p., every three days for 7 days) significantly upregulates TRPV1 protein expression in the bladders of naive rats.

  • 1/16

    Cyclophosphamide hydrate purchased from MedChemExpress. Usage Cited in: Life Sci. 2020 Aug 1;254:117590. [Abstract]

    Customer Validation
     Cyclophosphamide (75 mg/kg; i.p., every three days for a total of four times). CGA inhibits the MAPK/NF-κB pathway in CYP (Cyclophosphamide)-induced IC (n = 5). Western blotting detects the phosphorylation of p-ERK1/2, p-38, p-JNK, p-NF-κB (p-p65), and p-IκB proteins in the MAPK/NF-κB pathway in each group.

  • Cyclophosphamide hydrate